Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Adi Diab, Alison Martin, Lauren Simpson, Alain Patrick Algazi, Purvi Chawla, Dae Won Kim, Sourav Santra, Vruti Patel, Nitin Jadhav, Dhiraj Abhyankar, Michael A. Davies, Shama C. Buch, Kevin Kim, Adil Daud | ||||||||||||
Title | Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/153239-156 | ||||||||||||
Abstract Text | J Clin Oncol 33, 2015 (suppl; abstr 9076) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Voruciclib | Voruciclib | 0 | 1 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Voruciclib | P1446A-05 | CDK4/6 Inhibitor 14 | Voruciclib (P1446A-05) is a selective CDK4/6 inhibitor that results in cell cycle arrest and apoptosis in cancer cells (J Clin Oncol 33, 2015 (suppl; abstr 9076), PMID: 32296028). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF mutant | melanoma | sensitive | Vemurafenib + Voruciclib | Phase I | Actionable | In a Phase I trial, Voruciclib (P1446A-05) and Zelboraf (vemurafenib) combination therapy demonstrated safety and preliminary efficacy, resulted in complete response in 33% (1/3) and partial response in 67% (2/3) of BRAFi-naïve melanoma patients harboring BRAF mutations (J Clin Oncol 33, 2015 (suppl; abstr 9076)). | detail... |